News and Announcements
Invigor Group (ASX:IVO) Raising $2.5M to Fully Integrate the Acquisition of Sprooki
- Published June 23, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Data Solutions company Invigor Group (ASX:IVO) is planning to raise $2.5 million via the issue of convertible notes to sophisticated investors to fund its growth strategy.
KEY TAKEAWAYS:
- The funds will be used to provide additional working capital to Invigor to fund expansion of sales and marketing, and fully integrate the acquisition of Sprooki.
- The acquisition is expected to enhance Invigor’s position in loyalty and data analytics for retail and e-commerce.
- The acquisition will give Invigor an increased customer base, an expanded geographic footprint and a comprehensive product offering to leverage existing customers for further growth.
- Invigor is aiming to offer a comprehensive suite of data centric solutions that provide powerful defences and opportunities for retail and brands to combat new market entrants such as Amazon.
Sprooki is a provider of shopper engagement and loyalty solutions in Asia with a customer footprint of 18 shopping malls and several thousand retailers across six markets. The new ground funding will provide the company with financial flexibility to fund growth opportunities.
Invigor currently tracks more than 95,000 products across 40 industry verticals, gathering market intelligence data from over 950,000 product page URLs across hundreds of websites.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
